See analyst estimates and all valuation multiples for Nutraceuticals & Cosmeceuticals
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $26.5B | 1.7x | 7.2x | |
| $19.2B | 17.0x | 52.7x | |
| $16.3B | 10.6x | 32.2x | |
| $10.5B | 3.2x | 8.0x | |
| $7.1B | 4.6x | 23.4x | |
| $6.8B | 9.0x | 33.6x | |
| $3.7B | 10.4x | 24.2x | |
| $3.5B | n/a | n/a | |
| $3.4B | 1.6x | 9.6x | |
| $3.0B | 2.2x | 8.1x | |
| $2.8B | 1.3x | 8.9x | |
| $1.7B | 5.7x | 11.0x | |
| $1.6B | n/a | n/a | |
| $1.3B | 2.3x | 11.6x | |
| $1.2B | 5.5x | 20.9x | |
| $1.1B | 8.6x | 32.5x | |
| $1.1B | 6.8x | 23.0x | |
| $1.1B | 1.0x | 4.1x | |
| $941M | n/a | n/a | |
| $887M | 3.6x | 9.3x | |
| $882M | n/a | n/a | |
| $717M | 1.6x | 7.9x | |
| $590M | 13.9x | 39.7x | |
| $540M | 3.7x | 14.2x | |
| $538M | 4.5x | 35.7x | |
| $492M | n/a | n/a | |
| $481M | n/a | n/a | |
| $199M | 2.5x | 13.9x | |
| $192M | 2.9x | n/a | |
| $123M | 2.0x | 10.6x | |
| $91.4M | n/a | n/a | |
| $69.1M | n/a | n/a | |
| $66.8M | 4.9x | 68.4x | |
| $50.4M | 1.2x | 4.4x | |
| $27.8M | n/a | n/a | |
| $21.4M | 1.1x | -12.5x | |
| $18.7M | n/a | n/a | |
| $13.0M | 10.3x | -1.2x | |
| $7.8M | n/a | n/a | |
| $6.4M | n/a | n/a | |
| $4.8M | n/a | n/a | |
| -$2.8M | n/a | n/a | |
| -$64.2M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Nutraceuticals & Cosmeceuticals